We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ryanair (RYAAY) Hurt by Low Travel Demand and MAX Groundings
Read MoreHide Full Article
We recently issued an updated report on Ryanair Holdings plc (RYAAY - Free Report) .
The company, like other carriers, is bearing the brunt of plummeting air-travel demand due to the COVID-19 pandemic. The company’s fiscal 2020 profits were hurt by more than €40 million. The airline’s traffic fell more than 5 million in the period due to travel restrictions and aircraft groundings. With apprehensions about fleet grounding in April, May and June, the carrier expects to operate less than 1% of its total scheduled flights in the first quarter of fiscal 2021.
Consequently, Ryanair expects to incur a loss of more than €200 million in the fiscal first quarter. During fiscal 2021, the carrier expects to transport less than 80 million passengers that indicates an approximate 50% drop from its original target of 154 million passengers.
Additionally, the company is taking a hit from the Boeing 737 MAX groundings. Due to delivery delays of the aircraft, the company does not expect to receive its first MAX aircraft before October 2020. High fuel costs are also hurting Ryanair's bottom line. Notably, fuel bill increased 14% year over year in fiscal 2020.
However, Ryanair’s strong liquidity position looks impressive. Ryanair’s cash and cash equivalents at the end of fiscal 2020 stood at €2.57 million, higher than short-term debt of €382.3 million. This indicates that the company has enough cash to meet its short-term debt burden.
The Zacks Consensus Estimate for The Scorpio Tankers’ current-year earnings has been revised upward in excess of 100% in the past 60 days.
The Teekay Tankers stock has seen the Zacks consensus estimate for current year earnings being revised upward by 53% in the past 60 days.
The Zacks Consensus Estimate for Nordic AmericanTankers’ current-year earnings has been revised upward by 36.9% in the past 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Ryanair (RYAAY) Hurt by Low Travel Demand and MAX Groundings
We recently issued an updated report on Ryanair Holdings plc (RYAAY - Free Report) .
The company, like other carriers, is bearing the brunt of plummeting air-travel demand due to the COVID-19 pandemic. The company’s fiscal 2020 profits were hurt by more than €40 million. The airline’s traffic fell more than 5 million in the period due to travel restrictions and aircraft groundings. With apprehensions about fleet grounding in April, May and June, the carrier expects to operate less than 1% of its total scheduled flights in the first quarter of fiscal 2021.
Consequently, Ryanair expects to incur a loss of more than €200 million in the fiscal first quarter. During fiscal 2021, the carrier expects to transport less than 80 million passengers that indicates an approximate 50% drop from its original target of 154 million passengers.
Additionally, the company is taking a hit from the Boeing 737 MAX groundings. Due to delivery delays of the aircraft, the company does not expect to receive its first MAX aircraft before October 2020. High fuel costs are also hurting Ryanair's bottom line. Notably, fuel bill increased 14% year over year in fiscal 2020.
However, Ryanair’s strong liquidity position looks impressive. Ryanair’s cash and cash equivalents at the end of fiscal 2020 stood at €2.57 million, higher than short-term debt of €382.3 million. This indicates that the company has enough cash to meet its short-term debt burden.
Ryanair Holdings PLC Price
Ryanair Holdings PLC price | Ryanair Holdings PLC Quote
Zacks Rank & Stocks to Consider
Ryanair currently carries a Zacks Rank #5 (Strong Sell).
A few better-ranked stocks in the Zacks Transportation sector are Scorpio Tankers Inc. (STNG - Free Report) , Teekay Tankers Ltd. (TNK - Free Report) and Nordic American Tankers Limited (NAT - Free Report) . Scorpio Tankers and Teekay Tankers sport a Zacks Rank #1 (Strong Buy), while Nordic American Tankers carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for The Scorpio Tankers’ current-year earnings has been revised upward in excess of 100% in the past 60 days.
The Teekay Tankers stock has seen the Zacks consensus estimate for current year earnings being revised upward by 53% in the past 60 days.
The Zacks Consensus Estimate for Nordic AmericanTankers’ current-year earnings has been revised upward by 36.9% in the past 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>